Evidence map›Paper›PMID 40866261›Full record

ReviewInternal medicine (Tokyo, Japan)2026

Current Overview of Multi-omics Analyses in Microscopic Polyangiitis and Granulomatosis with Polyangiitis.

Atsuko Tsujii Miyamoto, Atsushi Kumanogoh, Masayuki Nishide

Abstract readReview
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Atsuko Tsujii MiyamotoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Masayuki NishideDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterized by autoantibodies against neutrophil cytoplasmic antigens such as myeloperoxidase (MPO) and proteinase 3 (PR3). AAV affects small blood vessels, leading to systemic inflammation and multiorgan damage. Recent advances in multi-omics analyses, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have significantly improved our understanding of AAV complex pathophysiology. Genome-wide association studies (GWASs) have revealed robust genetic associations, especially within the human leukocyte antigen (HLA) region. Epigenomic analyses have elucidated regulatory mechanisms that affect autoantigen gene expression and disease activity. Transcriptomic approaches, particularly single-cell RNA sequencing (scRNA-seq), have identified distinct gene expression profiles and cellular interactions, which have been further enriched by the recent application of spatial transcriptomics of diseased tissues. Proteomic and metabolomic approaches have been used to identify potential biomarkers. This review discusses recent advances in multi-omics research aimed at developing personalized diagnostic and therapeutic strategies based on the molecular and genetic profiles of AAV.

Indexed as

GenomicsGranulomatosis with PolyangiitisMicroscopic PolyangiitisBiomarkersEpigenomicsGenome-Wide Association StudyHumansMetabolomicsMultiomicsProteomicsTranscriptomeBiomarkersANCA-associated vasculitisgenomicsproteomicsscRNA-seqspatial transcriptomicstranscriptomics

Identifiers

PMID40866261
PMCPMC12900602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.